Skip to main content
OpenTrials
Completed

NCT Number: NCT05465889

Efficacy and Safety of Oral Sulfate Solution on Bowel Preparation for Colonoscopy

To evaluate whether oral sulfate solution used for colon cleaning in adults prior to colonoscopy was not inferior to 3-liter polyethylene glycol in the proportion of subjects with BBPS score (total colon) ≥6 after colonoscopy

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bowel Preparation for Colonoscopy

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Changhai Hospital

Shanghai, China

About this study

Polyethylene glycol (PEG) is the most widely used laxative at present, but volume of oral PEG liquid is large and the taste of PEG is not good, so some patients could not take enough laxative to complete bowel preparation. Oral sulfate solution containing sodium sulfate, magnesium sulfate, and potassium sulfate as active ingredients was developed as osmotic laxative for bowel cleansing preparation. The OSS works on the principle that sulfate is a poorly absorbed anion. Compared to traditional magnesium sulfate solution, OSS not only tastes better, but also reduces the occurrence of electrolyte disturbances.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntarily participate and sign informed consent;
  • Scheduling screening, surveillance, and diagnostic colonoscopy;
  • Necessary body fluid and blood electrolyte balance (the test values of potassium, sodium, chlorine, calcium and magnesium in blood biochemistry during screening period should not exceed 10% of the normal range).

Exclusion criteria

  • Subjects who used drugs that affect gastrointestinal dynamics, affect kidney function, or increase the risk of fluid retention or electrolyte disorders within 7 days before the start of the trial;
  • Subjects with serious cardiac and cerebrovascular diseases, bronchial and lung diseases, suffering from metabolic disease or endocrine disease, abnormal blood clotting mechanism, malignant tumor, electrolyte abnormalities, epilepsy, Renal or liver dysfunction;
  • Subjects with confirmed or suspected gastrointestinal obstruction, gastric retention, gastroparesis, gastric emptying disorder or acute gastrointestinal bleeding;
  • Subjects with acute severe colitis (such as active severe inflammatory bowel disease, acute bacterial dysentery, diverticulitis, etc.);
  • Subjects with a history of major gastrointestinal surgery (e.g. gastric bypass, gastric septal surgery, colostomy, colectomy, etc.);
  • Subjects with constipation or suspected severe gastric motility disorder;
  • Women with positive pregnancy tests or pregnancy plans, and women in lactation;
  • Subjects who have participated in any other clinical trials within the last 3 months;
  • Subjects with any other conditions that the investigator considered inappropriate for inclusion.

Treatment and study plan

Oral sulfate solution (OSS)

Drug

OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.

Polyethylene Glycol Electrolyte

Drug

Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.

Primary outcomes

  1. Bowel preparation adequate rate

    Time frame: 30 minutes

    Proportion of subjects with total Boston bowel preparation scale (BBPS) score (total colon) ≥6.

Secondary outcomes

  1. Boston bowel preparation scale (BBPS) score

    Time frame: 30 minutes

    The BBPS scoring rules: 0, unprepared colon segment with mucosa not seen because of solid stool that cannot be cleared; 1, portion of mucosa of the colon segment seen, but other areas of the colon segment are not well seen because of staining, residual stool, and/or opaque liquid; 2, minor amount of residual staining, small fragments of stool, and/or opaque liquid, but mucosa of colon segment is seen well; 3, entire mucosa of colon segment seen well, with no residual staining, small fragments of stool, or opaque liquid. the higher the score, the better the quality of bowel preparation.

    3 intestinal segments were scored separately: the right side of the colon (including the cecum and ascending colon), the transverse section of the colon (including the hepatic and splenic flexures), and the left side of the colon (including the descending colon, sigmoid colon, and rectum).

    Total BBPS score (0-9, the higher the score, the better the quality of bowel preparation).

  2. Acceptability of laxatives by questionnaire survey

    Time frame: 12 hours

    The proportion of people who accept the laxative. Level I: the laxative has good taste and is easy to take; the intestinal clearing fluid is drunk smoothly; the intestinal preparation process is easily tolerated; Level II: The laxative has a general taste and is easy to take. The intestinal fluid is basically drunk on time, and the intestinal preparation process is barely tolerated; Level III: unacceptable laxative taste, difficult to take medicine, unable to drink the clear bowel fluid on time, intolerable bowel preparation process, refuse similar experience in the future. Under level I and Level II, the laxative was considered to be acceptable. Under level III, the laxative was considered not to be acceptable.

  3. Colonoscopy completion rate

    Time frame: 30 minutes

    Proportion of subjects receiving complete colonoscopy

  4. Incidence of laxative-related adverse events assessed by clinical examinations

    Time frame: 8 days

    Physical examination (skin, mucous membranes, lymph nodes, head, neck, chest, abdomen, limbs), vital signs (temperature, respirations, heart rate, blood pressure), blood routine, urine routine, blood biochemistry (DBIL, TBIL, UREA, Cr, AST, ALT, TP, ALB, GLU, TG, TC, CK, ALP, K, Na, Cl, Ca, Mg, UA), coagulation function, and 12-lead electrocardiogram were performed within 7 days before taking laxatives. The clinical examinations were repeated on the same day after the colonoscopy. All abnormal changes in clinical examination results will be assessed by clinical specialists to determine if they are related to laxative intake. Incidence was calculated as the number of subjects with laxative-related adverse events divided by the total number of subjects.

Sponsors and collaborators

Lead sponsor

Changhai Hospital

Other

Collaborators

  • Beijing Hospital
  • China-japan Friendship Hospital, Jilin University
  • Hebei Provincial People's Hospital
  • Henan Provincial People's Hospital
  • Shandong University Qilu Hospital
  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  • Shanghai Hospital of Integrated Traditional Chinese and Western Medicine
  • The First Affiliated Hospital of Nanchang University
  • Zhongshan Hospital Xiamen University

Registry information

Official study title

Comparison of the Efficacy and Safety of Oral Sulfate Solution and 3-liter Polyethylene Glycol on Bowel Preparation Before Colonoscopy: a Multicenter Randomized Controlled Phase III Trial

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jul 20, 2022
Registry last updated
Jul 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.